Observational studies reveal that insomnia affects 4265% of cirrhosis patients
These studies provide insight into cancer risk, as they lasted only days to weeks, involved tiny samples, and measured only acute tolerability without assessing carcinogenic potential or effects on pre-existing malignancies
Frequency: Once per day (subcutaneous), ideally 3060 minutes before bedtime
The answer might be sitting in your endocrine system, quietly sabotaging everything you're w
Future directions include prospective randomized controlled trials where the present findings are replicated with more detailed questionnaires and other tests for fatigue, depression, sleep, and stress
Loading Phase (Weeks 1-4): 2 to 2.5 mg twice weekly (Monday/Thursday schedule) Maintenance Phase (Weeks 5+): 2 mg once every 7 to 14 days Administration: Subcutaneous injection, location flexible due to systemic distribution Total Cycle: 8 to 12 weeks with 4 to 8 weeks off between cycles The convenience of twice-weekly dosing during loading and weekly or biweekly dosing during maintenance fits easily into Retatrutide schedules
